NCT04972422 is a Phase 1 clinical trial of ZN-c3 in Solid Tumors, sponsored by Zentera Therapeutics HK Limited.

Who is sponsoring NCT04972422?

NCT04972422 is sponsored by Zentera Therapeutics HK Limited.

What drugs are being tested in NCT04972422?

Interventions in NCT04972422: ZN-c3.

What condition does NCT04972422 study?

NCT04972422 studies Solid Tumors.

Is NCT04972422 still recruiting?

NCT04972422 is currently status unknown. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT04972422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1b Study of ZN-c3 in Chinese Subjects

Status unknown Phase 1 Last updated 5 September 2021

What this trial tests

Phase 1 trial testing ZN-c3 in Solid Tumors in 38 participants. Status unknown.

Timeline

15 July 2021

Primary endpoint
30 June 2022

30 June 2023

Quick facts

Lead sponsor	Zentera Therapeutics HK Limited
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	15 July 2021
Primary completion	30 June 2022
Estimated completion	30 June 2023
Sites	3 locations across China

Drugs / interventions tested

ZN-c3 (zn-c3) — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

Zentera Therapeutics HK Limited

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the DNA damage response for cancer therapy.
Curtin NJ. · · 2023 · cited 30× · PMID 36606678 · DOI 10.1042/bst20220681
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli VJ, Yadav P, Suresh V, Jadav SS. · · 2023 · cited 18× · PMID 37323408 · DOI 10.1021/acsomega.3c01558
Targeting the DNA damage response in cancer.
Federica G, Michela C, Giovanna D. · · 2024 · cited 12× · PMID 39492835 · DOI 10.1002/mco2.788
Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update.
Zhang Z, Harish R, Elahi N, Saini S, et al · · 2025 · cited 2× · PMID 40565165 · DOI 10.3390/ijms26125701

Verify or expand the search:

Other trials of ZN-c3

Trials testing the same drug.

NCT05743036 — ZN-c3 in Adult Participants With Metastatic Colorectal Cancer · Phase 1 · terminated
NCT05431582 — Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors · Phase 1 · withdrawn
NCT05682170 — Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) · Phase 1, PHASE2 · terminated

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Zentera Therapeutics HK Limited trials

Trials by the same sponsor.

NCT05127811 — A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma · Phase 1 · terminated
NCT04852419 — A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04972422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zentera Therapeutics HK Limited
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing